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Introduction
Periosteal osteosarcoma is a well-de￿ ned patholog-
ical entity with characteristic radiological and histo-
logical features. First recognized by Ewing in 19391
it was only described as a separate entity in 1955 by
Litchenstein.2 Unni in 19763 produced the ￿ rst large
series about this condition, whilst Campanacci in the
same year recommended wide excision to maximize
cure.4 It is a rare tumour, representing no more than
1–2%  of  all  osteosarcomas  and  the  number  of
patients appearing in the world literature is small.
Controversy remains about the appropriate treat-
ment of periosteal osteosarcoma. All are agreed that
complete  surgical  excision  is  mandatory  for  local
control but the role of chemotherapy in this condi-
tion is still debatable.Previous analyses have reported
relatively  high  numbers of  tumour related  deaths,
particularly  early  studies.3–7 The  main  identi￿ able
risk factor for early death is inadequate margin of
surgical excision. Only Hall et al. report no metas-
tases in their sample of six patients.
We present a series of 17 patients treated at our
centre  over  16  years. Our  patients  received
chemotherapy when the tumour showed high-grade
histological features or when there was evidence of
medullary involvement.To date no patients have died
as a direct result of their osteosarcoma or of related
treatment. We  examine  possible  reasons  for  this
encouraging survival  rate  and discuss the  implica-
tions for therapeutic approaches in this condition.
Patients and methods
In our unit,patient,diagnostic and treatment data are
collected  prospectively  on  a  computer  database.
Review  of  this  showed  that  17  patients  had  been
diagnosed  as  having  a  periosteal  osteosarcoma
between 1983 and 1999. There were 10 males and
seven females with an age range from 10 to 35 years
and a median of 18 years (Table 1). Five tumours
arose in the proximal tibia and four in the proximal
femur (Fig. 1).
All patients underwent a full staging  procedure8
with bone scintigraphy,CT scan of chest and MRI or
CT of the tumour itself.
Radiological ￿ ndings were consistent with a diag-
nosis of periosteal osteosarcoma in all cases, showing
a tumour on the periosteal surface of the bone, with
the epicentre outside the bone and typical stippled
calci￿ cation (Fig. 2a,b).
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diagnosis reviewed the specimens.Medullary involve-
ment,bony and soft tissue resection margins,grade of
tumour and percentage necrosis, if applicable, were
con￿ rmed. Features  typical  of  periosteal  osteosar-
coma were considered to be:a tumour forming a lob-
ulated  pattern  with  malignant  spindle cells  at  the
periphery of the nodules. Centrally, the lobules had
malignant cartilage containing areas of endochondral
calci￿ cation and seams of osteoid (Fig. 3a,b).
All  patients  underwent  surgery  to  excise  the
tumour.The primary surgical procedures used were
simple excision in four cases,excision with bone graft
in three or excision and insertion of an endopros-
thesis in the remaining 10 (Table 2).
Fourteen of the 17 cases received chemotherapy,
the usual regime being a combination of cisplatin and
doxorubicin  as  would  be  used  for  conventional
osteosarcoma.9,10Ten of the patients received neoad-
juvant  chemotherapy, whilst  four  only  received  it
following  surgical excision. Three  patients  did not
receive chemotherapy where it was considered there
would be no added bene￿ t in addition to surgery.
One  patient  received  radiotherapy  in  addition  to
chemotherapy because of a high-grade tumour and
close margins of excision.
Patient notes were analyzed with particular regard
to operative management, other treatment modali-
ties, recurrence, metastasis and death. Axial images
were examined with a hand-held angle measure to
quantify the circumferential extent of the tumour.
Results
Biopsy results
Of  the  17  patients, seven  had  the  diagnosis  of
periosteal osteosarcoma con￿ rmed at the time of the
original biopsy. Of these, four biopsies were done at
our  centre  and  three  were  done  elsewhere. Ten
patients had an initial inconclusive biopsy, the most
common  differential  diagnosis  being  a  periosteal
chondroma. Confusion was sometimes apparent in
patients having needle biopsies in which only small
samples were obtained. In these cases, the diagnosis
was  only eventually  con￿ rmed following  complete
rebiopsy or excision of the lesion.
Tumour variables
The maximum dimension of the tumour varied from
4  to 13.5 cm (mean 7.9 ± 2.7 cm).On axial imaging,
the  tumour was  found to  encircle between  5  and
100% of the cortex of the bone. Histologically all the
tumours  were  intermediate  or  high  grade.11,12
Medullary  involvement  was  demonstrable  in  four
specimens. One contained demonstrable tumour in
the profunda vein. Percentage necrosis was recorded
for the tumours of those patients who had undergone
chemotherapy preoperatively. Only two of these 10
patients  who  received  neoadjuvent  chemotherapy
had greater than 90% necrosis.
Surgery
Ten patients had complete excision of the tumour
and replacement of the involved bone with an endo-
prosthesis as the ￿ rst surgical intervention.The soft
tissue margins of excision were often 1 mm or less as
the muscles frequently ‘fell away’ from the surface of
the tumour.The bony resection margins were judged
clear in all cases.
Three patients underwent excision of the tumour
without reconstruction in an attempt to ‘shark bite’
the tumour. In these cases, the bony margins of exci-
sion proved positive in two cases and, as a result, two
have required re-excision and one has  gone on to
have  a  metal  endoprosthesis. In  those  treated
primarily  with  excision  and  bone  grafting, the
124 Revell et al.
Table 1. Ages of patients with periosteal osteosarcoma
Decade of life Number
10–19 5
20–29 9
30–39 3
40–49 4
Fig. 1. Site of tumour.margins  of  excision  were  clear  in  all  cases. One
patient required internal ￿ xation then endoprosthesis
for non-union.
Local control
There was one case of local recurrence in a patient
who had what was planned as a wide local excision
but in whom the excision margins proved positive.
He  had  chemotherapy  postoperatively  but  subse-
quently developed local recurrence after 12 months
at the site of the tumour excision margin. He then
underwent  a  further  complete  resection  of  the
involved bone with wide margins and insertion of an
endoprosthesis.This became infected and he elected
to have an above knee amputation.
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Fig. 2. (a) Plain radiograph of a humerus showing many typical features of a periosteal osteosarcoma in the diaphyseal region.
(b) Magnetic resonance image of the same tumour, showing eccentric epicentre and near encirclement.
(a)
(b)126 Revell et al.
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7Survival
The mean follow-up is 82 ± 53 months (range 9–200
months). No  patient  has  developed  metastases  to
date. Fifteen of the 17 patients are still living. One
patient developed acute myeloid leukaemia 10 years
following chemotherapy and endoprosthetic replace-
ment of the proximal femur. A second patient, who
had also undergone proximal femoral endoprosthesis
and chemotherapy, died 10 years later of a primary
brain tumour.
Discussion
The  de￿ nition  of  periosteal  osteosarcoma  is  very
precise.13 Importantly it is essential to exclude high-
grade surface osteosarcomas and parosteal osteosar-
comas from this group.We did not exclude patients
with medullary involvement from the study. In cases
where the histological and radiological ￿ ndings were
otherwise  typical  they  were  included  for  analysis.
Unni  et  al. originally  included  no  cases  where
medullary  involvement  was  present. Hall  et  al.,
however, argued persuasively that medullary involve-
ment  did  not  preclude  a  diagnosis  of  periosteal
osteosarcoma. If the possibility of including cases of
intramedullary osteosarcoma in the group is enter-
tained, this could reasonably be expected to elevate
the average grade of tumour and adversely affect the
survival statistics.
Our survival ￿ gures are very encouraging and our
100% metastasis-free survival during a mean follow-
up over 10 years represents one of the best survival
￿ gures yet published. The reasons for this are not
immediately apparent but may well be due to two
factors. Firstly the radical resection of the tumour,
preventing local recurrence which is known to be a
risk  factor  for  the  subsequent  development  of
metastatic disease in high-grade osteosarcoma14 and
secondly the use of chemotherapy.
Many authors have highlighted the high incidence
of  local  recurrence  in  periosteal  tumours  when
complete  excision  is  not  achieved. The  natural
tendency to try and preserve the patients bone by
doing  a  ‘shark-bite’ procedure  may  risk  leaving
tumour behind, as  was  found in two  of  our cases
where this was attempted. One of the problems with
this  sort  of  surgery  is  actually  assessing  the  true
extent of the tumour in the subperiosteal plane and
even with axial MRI and CT this can be dif￿ cult. It
is likely that the tumour spreads further than can be
imaged  using  these  modalities  and  hence  wider
margins than might at ￿ rst be considered are manda-
tory  for  safety. Masterson  et  al. described  this 
procedure as the ‘geometric osteotomy’ but only had
one  periosteal  osteosarcoma  in  their  series  of  12
cases.15 They achieved negative margins in all their
cases but had  one local  recurrence in a  periosteal
chondroma. The  average  percentage  of  cortex
circumference  involved  in  their  series  was  30%,
although one patient had 50% involvement. In our
group, the  percentage  circumference  varied  more
greatly from a small cortical lesion to complete encir-
clement.
Our low rate of local recurrence is, however, at the
expense of a large proportion of patients undergoing
limb salvage surgery with endoprostheses.These pro-
vide a good guarantee of local control and early return
of function, but do increase the long-term risks of
problems with the limb due to complications such as
infection, loosening and prosthetic failure.16–19 The
relative risks of cure of the disease need to be balanced
with the long-term risks to the limb with these meth-
ods of limb salvage.Given the uncertainty of outcome
with  local  resection  and  the  improving  results  of
major resection and limb salvage surgery, we believe
that every attempt to obtain wide margins at the ￿ rst
surgical procedure should be made.
Our patient group shows improved survival when
compared with previously reported series.Rasquinha
et al.reported on a very similar series to ours and had
three local recurrences and three deaths, of whom
two were due to other causes.20 They too suggested
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Fig.3. (a) Lobules of neoplastic cartilage and primitive bone matrix undergoing mineralisation.The tumour is of intermediate grade
(H&E stain, (40)). (b) High-grade tumours also showed undifferentiated mesenchymal cells with osteoid matrix deposition (H&E
stain, (100)).128 Revell et al.
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importance of complete surgical excision. Figures of
local recurrence and survival, as far as they are com-
parable, are summarized in Table 3. Survival curves
derived from original data are shown in Fig. 4.
One noticeable feature in many series,including our
own,is the high incidence of deaths from causes other
than  osteosarcoma. A death from acute myelocytic
leukemia (AML) is reported in our own series and
there are two cases of AML in the account of Ritts 
et al. One of our patients died of a brain tumour, 21
although it has not been possible to elucidate the his-
tological type. It seems likely that environmental or
genetic predisposition to  tumours accounts for the
majority of these cases. It is of particular interest that
one of our patients came from a ‘p53 family’,a sibling
having  previously been treated for a brain tumour.
Another possibility is that treatments have given rise to
an increased risk of malignancy in later life. However,
the inconsistency between centres of adjuvant thera-
pies does not lead the authors to the conclusion that
such a pattern can be found from the data so far.
We believe that the impressive disease-free survival
￿ gures in this series are a re￿ ection of the aggressive
surgical resection policy combined with the use of
chemotherapy for all patients with  high-grade  ele-
ments of the tumour.Historical series have suggested
that overall survival is about 70% without chemother-
apy,unfortunately it has thus far proved impossible to
identify the 30% of patients who are the ones most at
risk and who thus might bene￿ t from chemotherapy.
Until this is clear-cut, it would seem prudent to con-
tinue to treat all patients with high-grade areas or
medullary  involvement  with  this  combination  of
chemotherapy  and  wide  surgical  resection. It  is
unlikely that a randomized study will ever answer this
question for such a rare disease. Similarly, the role of
neo as opposed to adjuvant chemotherapy is unclear
but, given  the  tendency  to  treat  all  high-grade
osteosarcoma  with  neoadjuvant  chemotherapy, it
seems  sensible  to  do  the  same  for  all  periosteal
osteosarcoma with a biopsy-proven diagnosis.
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